No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
US OptionsDetailed Quotes
CRDF241220C2500
- 1.31
- +0.66+101.54%
15min DelayClose Dec 13 16:00 ET
1.60High1.15Low
1.15Open0.65Pre Close10 Volume881 Open Interest2.50Strike Price1.47KTurnover0.00%IV-2.81%PremiumDec 20, 2024Expiry Date1.42Intrinsic Value100Multiplier6DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma2.80Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Intraday
- 5D
- Daily
News
Cardiff Oncology Is Maintained at Overweight by Piper Sandler
Cardiff Oncology Analyst Ratings
Piper Sandler Maintains Cardiff Oncology(CRDF.US) With Buy Rating, Raises Target Price to $10
TD Cowen Maintains Cardiff Oncology(CRDF.US) With Buy Rating
Cardiff Oncology Director Gary Pace Buys $940,199 in Stock
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study